Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory infections in infants, often resulting in hospitalisation. A recent study from Galicia, Spain, demonstrates the effectiveness of nirsevimab, a long-acting monoclonal antibody, in preventing RSV-related hospitalisations during the 2023-2024 season.